Close Menu

NEW YORK – Allarity Therapeutics said on Friday that it has submitted a premarket approval application to the US Food and Drug Administration for its DRP platform for use as a companion diagnostic alongside the kidney cancer drug dovitinib.

Allarity, formerly known as Oncology Venture, licensed the pan-tyrosine kinase inhibitor dovitinib from Novartis after it failed to demonstrate a benefit for an all-comer kidney cancer population. Now, Allarity plans to seek FDA approval for the drug in a biomarker-selected population of kidney cancer patients, as determined by the DRP.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.